

Curriculum Vitae
Joy S. Hogan, LPN ph, CCRC

Signature:
Date Signed:

Joy S. Hogan
6/30/08

Business Address:

CAMC Health Education and
Research Institute
Clinical Trials Center
3100 MacCorkle Avenue, SE
Suite 306
Charleston, WV 25304
Phone: (304) 388-9957
Fax: (304) 388-9935
Email: joy.hogan@camc.org

EDUCATION:

- 1993 Diploma of Licensed Practical Nursing with Pharmacology
Garnet Career Center / School of Practical Nursing
Charleston, WV
- 1976 Diploma
Sissonville High School
Sissonville, WV
- 1975 Certificate of Medical / Nursing Assistant
Benjamin Franklin Technical Center
Dunbar, WV

PROFESSIONAL EXPERIENCE:

- 2005 – Present Certified Clinical Research Coordinator
CAMC Health Education and Research Institute / Clinical Trials Center
Charleston, WV
- 2002 – 2005 Clinical Research Coordinator
CAMC Health Education and Research Institute / Clinical Trials Center
Charleston, WV
- 2001 – 2002 LPN ph / Post Cardiac Catherization Unit
CAMC Memorial Division
Charleston, WV
- 1993 – 2000 LPN ph / Scrub Tech Cardiac Cath. Lab
CAMC Memorial Division
Charleston, WV
- 1993 – 1993 LPN ph / Orthopedic Floor
CAMC General Division
Charleston, WV

1990 – 1992 Medical Assistant
Dr. David M. Ritchie
Charleston, WV

1989 – 1990 Donor Room Supervisor
Alpha Therapeutic Corporation
Charleston, WV

1982 – 1985 Phlebotomist / Courier
Litton Bionetics Medical Laboratories
Charleston, WV

1981 – 1982 Phlebotomist
CAMC Memorial Division
Charleston, WV

1980 – 1981 Nursing Assistant
CAMC General Division
Charleston, WV

1979 – 1980 Medical Assistant
Dr. Jerry W. Eden
Charleston, WV

PROFESSIONAL AFFILIATIONS:

West Virginia State Board of Examiners for Licensed Practical Nurses
Association of Clinical Research Professionals

CERTIFICATIONS:

CPR – 2007
ACRP/Certified Clinical Research Coordinator – 2005
CITI – Course in The Protection of Human Research Subjects – 2005
Coordinating a Clinical Research Study – 2002
Human Participants Protection Education for Research Teams – 2002

CLINICAL RESEARCH EXPERIENCE:

7 Years of Research Experience to date

Certified Clinical Research Coordinator: the primary role of the Research Coordinator is to screen and assess the patients in accordance with the protocol for eligibility, baseline, and follow-up procedures. The research coordinator is also responsible for assisting in the informed consent process, completing all case report forms, collecting the data, and maintaining documents and correspondence with the sponsor. The coordinator also completes all internal and external regulatory requirements.

08-03-2035: *TRILOGY* - A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who Are Medically Managed, *Eli Lilly and Company*

HS# 07-10-1982: *RibX* - A Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of RX-3341 Compared with Cefazolin for the Prevention of Surgical Site Infections Following Coronary Artery Bypass Graft Surgery, *Rib-X Pharmaceuticals, Inc.*

HS# 07-07-1961: *MS-F204 Ext* - Protocol MS-F204 EXT: Open Label Extension Study to Evaluate the Safety, Tolerability, and Activity of Oral Fampridine-SR in Patients with Multiple Sclerosis who Participated in the MS-F204 Trial, *Acorda Therapeutics, Inc.*

HS# 07-06-1956: *CHOICE* - Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes through the Collection of Clinical Evidence (CHOICE), *Abbott Vascular*

HS# 07-04-1928: *HERCULES* - A Prospective, Non-Randomized, Multi-Center, Single-Arm Clinical Trial to Assess the Safety and Efficacy of the RX Herculink (R) Elite (TM) Renal Stent System for the Treatment of Suboptimal Post-Procedural Percutaneous Transluminal Angioplasty (PTA) in Atherosclerotic DeNovo or Restenotic Renal Artery Stenoses in Patients with Uncontrolled Hypertension (The HERCULES Trial), *Abbott Vascular*

HS# 07-02-1906: *MS-F204* - Protocol No. MS-F204 - Double Blind, Placebo-Controlled, parallel Group Study to Evaluate Safety and Efficacy of oral Fampridine-SR (10 mg b.i.d) in patients with Multiple Sclerosis, *Acorda Therapeutics, Inc.*

HS# 06-11-1874: *PFO ACCESS Registry* - Patient Foramen Ovale Closure with the AMPLATZER PFO OCCLUDER in Patients with Recurrent Cryptogenic Stroke due to Presumed Paradoxical Embolism through a Patent Foramen Ovale who have Failed Conventional Drug Therapy, *AGA Medical Corporation*

HS# 06-11-1869: *SMARTCHECK INR Accuracy* - Evaluation of the Accuracy of the SmartCheck INR Coagulation System in a Professional Point of Care Setting, *Inverness Medical Innovations*

HS# 06-11-1868: *SMARTCHECK INR Normal Range* - Determination of a Normal Reference Range for SmartCheck INR Coagulation System, *Inverness Medical Innovations*

HS# 06-09-1855: *MEND CABG II* - Protocol Number 06004: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardio Protective Effects of MC-1 in Patients Undergoing High Risk Coronary Artery Bypass Graft (CABG) Surgery, *Medicare International, Inc. /o Clinical Development Research Institute, (CDRI) Inc*

HS# 06-08-1843: *RESPECT* - A Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment, *AGA Medical Corporation*

HS# 06-04-1798: *VIBRANT* - Protocol Number SFA-05-03: GORE VIABAHN(R) Endoprosthesis versus Bare Nitinol Stent in the Treatment of Long Lesion (>8cm) Superficial Femoral Artery Occlusive Disease, *WL Gore & Associates, Inc.*

HS# 06-04-1797: *VIVA I / XCELL* – Protocol Number 00-105-644: Xpert™ Nitinol Stenting for Critically Ischemic Lower Limbs, *VIVA I Physicians, Inc.*

HS# 06-03-1790: *CAPTURE 2* – A Post-Approval Study of the Guidant Acculink Stent Systems and Accunet Embolic Protection Systems (Carotid RX ACCULINK/RX ACCUNET Post-Approval Trial to Uncover Unanticipated and Rare Events, *Guidant, Inc.*

HS# 06-01-1762: *ZoMaxx II* – Protocol Number 640-0048-04.1: A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx™ Drug Eluting Coronary Stent System as Compared to the TAXUS™ Express2™ Paclitaxel-Eluting Stent in de novo Coronary Artery Lesions, *Abbott Laboratories, Abbott Vascular Devices*

HS# 05-11-1738: *RAD* – Protocol Number CRAD001A2309: A 24-Month, Multicenter, Randomized, Open-Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration-Controlled Certican(R) in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral(R) versus 1.44g Myfortic(R) with Standard Dose Neoral in De Novo Renal Transplant Recipients, *Novartis Pharmaceutical Corporation*

HS# 05-11-1737: *EXACT* – Protocol Number 640-0063-01: Emboshield (R) and Xact (R) Post Approval Carotid Stent Trial Using the Emboshield BarWire(TM) Rapid Exchange Embolic Protections System and Xact (R) Rapid Exchange Carotid Stent System, *Abbott Vascular Devices*

HS# 05-09-1728: *AMIHOTT II* - Acute Myocardial Infarction with Hyperoxemic Therapy II: A Prospective, Multi-Center, Randomized, Study of Aqueous Oxygen Therapy for 90 Minutes In Anterior Acute Myocardial Infarction Patients with Successful Reperfusion (VIA PCI) <Six Hours After Symptom Onset, *TherOx, Inc.*

HS# 05-07-1707: *COSTAR II* - Cobalt Chromium STent with Antiproliferative for Restenosis II Trial, *Conor Medsystems, Inc.*

HS# 05-07-1704: *VIVA* - The VIVEXX Carotid Revascularization Trial for High Surgical Risk Patients with Extracranial Carotid Artery Stenosis using the Bard VIVEXX Carotid Stent and Emboshield Bare Wire Rapid Exchange Embolic Protection System, *Bard Peripheral Vascular, Inc.*

HS# 04-11-1650: *PRIMO CABG II* - Protocol: 2003141: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of 2mg/kg bolus plus 24 hour infusion of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting with Cardiopulmonary Bypass, *Alexion Pharmaceuticals, Inc. / Proctor & Gamble*

HS# 04-10-1641: *CAPTURE EV* - A Post Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems (Carotid RX Acculink/ Accunet Post-Approval Trial to Uncover Unanticipated or Rare Events, *Guidant Corporation*

HS# 04-08-1628: *CHOOSE On-Pump* – Protocol Number TMC-BIV-02-03: A Phase III Study of Angiomax (R) (bivalirudin) in Patients with HIT/HITTS Type II, Undergoing Cardiac Surgery on Cardiopulmonary Bypass (TMC CHOOSE), *The Medicines Company*

HS# 04-04-1598: *R vs C* - Protocol Number 24735: A Phase IV Multi Center, Open Label, Randomized Study of Rebif (R) 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared with Copaxone (R) 20mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis, *Serono, Inc*

HS# 04-03-1582: *PROPATEN* - Comparison of Primary Patency Between GORE-TEX(R) PROPATEN Vascular Grafts and Thin Walled GORE-TEX(R) Stretch Vascular Grafts, *W. L. Gore & Associates, Inc*

HS# 03-08-1511: *E VOLUTION Off-Pump* - A Study Comparing Angiomax® (bivalirudin) to Heparin with Protamine Reversal in Patients Undergoing Off-Pump Coronary Artery Bypass (OPCAB) Surgery. *The Medicines Company*

HS# 03-07-1507: *SCI-F300-EXT* - Protocol #: SCI-F300-EXT: Open-Label Extension of Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Chronic, Incomplete Spinal Cord Injury, *A corda Therapeutics*

HS# 03-06-1497: *ADEST* - Clinical Evaluation of the Concomitant Use of Bivalirudin (Angiomax (R) and a Drug-Eluting Stent, *The Medicines Company*

HS# 03-05-1489: *CHOOSE Off-Pump* - A Phase III Study of Angiomax (bivalirudin) in Patients with HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass (OPCAB) Surgery, *The Medicines Company*

HS# 03-02-1459: *PREVENT IV* - Protocol Number Protocol # CGT003-04 - A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment with CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures, *Corgentech Inc*

HS# 02-12-1433: *ARDS* - A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of Surfaxin(R) (Lucinactant) Delivered Via Bronchopulmonary Segmental Lavage to Standard of Care in Patients with Acute Respiratory Distress Syndrome, *Discovery Laboratories*

HS# 02-11-1426: *CVAL489 A 2302* - A Double-Blind, Randomized, Multicenter Study followed by 12 Months Open-label Treatment to Evaluate the Dose-response and Safety of Valsartan in Pediatric Hypertensive Patients, *Novartis Pharmaceuticals Corporation*

HS# 02-10-1416: *PRIDE* - TriActive™ System Randomized Multicenter Clinical Trial. Protection during Saphenous Vein Graft Intervention to Prevent Distal Embolization, *Kensey Nash Corporation*

HS# 02-09-1406: *MOBILE* - Protocol Number D00789: A Prospective, Phase III, Randomized Trial to Evaluate the Safety and Effectiveness of the Novoste™ Corona™ System for the Treatment of In-Stent Restenosis of Native Superficial Femoral Arteries (SFA) and Popliteal Arteries When Used Immediately After Successful Percutaneous Intervention, *Novoste Corporation*

HS# 02-09-1400: *VALIANT* - Protocol # G020143 Vascular Architects Femoropopliteal Sub-Optimal Angioplasty aSpire™ Stent Trial (REAL SFA), PTFE coated stent for the treatment of sub-

optimal/failed Percutaneous transluminal angioplasty (PTA) in stenotic or occluded superficial femoral arteries (SFA) or popliteal arteries above the tibial bifurcation. *Prairie Cardiovascular Consultants, Ltd.*

HS# 02-06-1377: *ED* - Protocol # A1481137 A Multicenter, Open-label, Flexible Dose Escalation Study to Evaluate the Correlation Between Event Log Parameters, Self Esteem/Overall Relationships, and Efficacy of Viagra (R) (Sildenafil Citrate) in Men with Erectile Dysfunction, *Pfizer Inc.*

HS# 02-06-1374: *AMPLATZER* - AMPLATZER® PFO Occluder, *AGA Medical, Inc.*

HS# 02-05-1366: *SYMBIOT III* - A Prospective Randomized Trial Evaluating the Symbiot III Covered Stent System in Saphenous Vein Grafts, *Boston Scientific Corporation*

HS# 02-04-1357: *TAXUS IV-SR* - Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent, *Boston Scientific Corporation*

HS# 02-04-1354: *SCI-F301* - Protocol SCI-F301: Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects with Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury, *Acorda Therapeutics, Inc.*

HS# 02-03-1346: *PLUS* – Protocol Number T3S201: A Randomized, Multicenter Trial of Transcutaneous, Low-Energy ultrasound Therapy with Thrombolysis for Patients with Acute Myocardial Infarction. PLUS Perfusion by Thrombolytic and UltraSound, *Tirris Systems, Inc.*

HS# 02-03-1345: *REPLACE 2* – Protocol TMC-BIV-01-03 A Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to reduced Clinical Events, Part 2, *The Medicines Company*

HS# 02-01-1328: *SHELHIGH* - Clinical Evaluation of the Shelhigh, Inc.™ Stentless Porcine Bioprostheses for Aortic Valve Replacement Model NR-2000 Plus™ and Model NR-2000C Plus No-ReactR Treated, *Shelhigh, Inc.*

HS# 01-07-1289: *JOSTENT* - Jostent Coronary Stent Graft System – Humanitarian Use Device, *JOMED, Inc.*

HS# 01-05-1272: *RENEW* - Protocol # 031.0007: A Prospective, Open-Label Tolerability and Safety Monitoring Study of Novantrone(R) (mitoxantrone) in a Selected Cohort of Multiple Sclerosis Patients, *Immunex Corporation*

HS# 00-11-1212 *CardioSeal* – Humanitarian Use Device Exemption for CardioSEAL® Septal Occluder, *NMT Medical, Inc.*

HS# 00-11-1209: *APO 401* - A Phase III, Prospective, Randomized, Placebo-Controlled, Parallel Groups Study of the Continued Efficacy and Safety of Subcutaneous Injection of Apomorphine in the Treatment of “Off” Episodes in Patients with “On/Off” or “Wearing-Off” Effects Associated

with Late-Stage Parkinson's Disease after Apomorphine Use for at least a Three Month Duration,
Mylan Pharmaceutical Laboratory, Inc.

+++ HS# is Internal study Identifier